TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2092880

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 352

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 352
Study: 340319

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Caloric supplementation
Number of subjects: 14
Study: 31415448

Group type: EXPERIMENTAL
Intervention: APP (smartphone application)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No-APP (hard copy training program)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: APP
Number of subjects: 38

Group type: COMPARATOR
Intervention: No-APP
Number of subjects: 38
Study: 31204683

Group type: EXPERIMENTAL
Intervention: Visualization of asymptomatic atherosclerotic disease
Number of subjects: 3532

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 3532
Study: 27109625

Group type: EXPERIMENTAL
Intervention: Foster care intervention (N=40)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Care-as-usual (N=40)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Never-institutionalized comparison group (N=47)
Number of subjects: 127
Study: 27840443

Group type: EXPERIMENTAL
Intervention: Focused shockwave therapy (FSWT; 2000 impulses, 4 Hz, 0.4 mJ/mm2)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Radial shockwave therapy (RSWT; 2000 impulses, 8 Hz, 5 bars + 2000 impulses, 8 Hz, 2.5 bars)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Focused shockwave therapy (FSWT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Radial shockwave therapy (RSWT)
Number of subjects: 43
Study: 25402398

Group type: EXPERIMENTAL
Intervention: iDecide (interactive, Web-based, tablet computer-delivered tool)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Print educational materials
Number of subjects: 188
Study: 23146640

Group type: EXPERIMENTAL
Intervention: Slow IANB with 3.6 mL of 2% lidocaine with 1:200,000 epinephrine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Rapid IANB with 3.6 mL of 2% lidocaine with 1:200,000 epinephrine
Number of subjects: 59
Study: 20725124

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (30 min aerobic + 30 min resistance training)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (60 min treadmill walking)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no activity)
Number of subjects: 38
Study: 18375320

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (7%) (1.2 mL/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline (0.9%) (1.2 mL/kg)
Number of subjects: 22
Study: 15750756

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2a plus ribavirin 1,000/1,200 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Interferon alpha-2a plus ribavirin 600 mg
Number of subjects: 27
Study: 12519136

Group type: EXPERIMENTAL
Intervention: Sevoflurane with 70% N2O (group A)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sevoflurane alone (group B)
Number of subjects: 114
Study: 10897707

Group type: EXPERIMENTAL
Intervention: Advanced postgraduate education module for nurses in continence care
Number of subjects: 0
Study: 8719151

Group type: EXPERIMENTAL
Intervention: Letters from physicians
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational pamphlet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Letters inviting attendance at a women's health clinic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 1533432

Group type: EXPERIMENTAL
Intervention: S+TV+H
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: S+TA+H
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: S+TV
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: H+TV
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: H+TA
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: S+H
Number of subjects: 1
Study: 3933617

Group type: EXPERIMENTAL
Intervention: Seven day course of amoxycillin 125 mg three times a day
Number of subjects: 274

Group type: COMPARATOR
Intervention: Two day course of amoxycillin 750 mg twice a day
Number of subjects: 274
Study: 31192975

Group type: EXPERIMENTAL
Intervention: Tigecycline 1.2 mg/kg every 12 hours for children 8-11 years and 50 mg every 12 hours for children 12 to <18 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 0
Study: 28573765

Group type: EXPERIMENTAL
Intervention: Dulaglutide (1.5 mg)
Number of subjects: 9901

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9901
Study: 27460482

Group type: EXPERIMENTAL
Intervention: Baseline drinking to cope with negative affect
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Baseline drinking due to social pressure
Number of subjects: 254
Study: 24239167

Group type: EXPERIMENTAL
Intervention: Xbox Kinect (XbK) training
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Traditional physiotherapy (TP) training
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (no balance training)
Number of subjects: 63
Study: 23401397

Group type: EXPERIMENTAL
Intervention: Exercise-only (EXO; 12-weeks exercise without diet-restriction)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (DIO; 8-weeks very low energy diet (VLED) + 4-weeks weight maintenance diet)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet and exercise (DEX; 8-weeks VLED + 4-weeks weight maintenance diet combined with exercise throughout the 12 weeks)
Number of subjects: 79
Study: 21247533

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiothoracic CT protocol
Number of subjects: 59

Group type: COMPARATOR
Intervention: Dedicated CT protocol
Number of subjects: 59
Study: 19807791

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with mixed nuts
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with virgin olive oil
Number of subjects: 238

Group type: COMPARATOR
Intervention: Recommended low‐fat diet (control diet group)
Number of subjects: 238
Study: 18001407

Group type: COMPARATOR
Intervention: omeprazole 20 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: rabeprazole 20 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: esomeprazole 40 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week
Number of subjects: 576
Study: 15143718

Group type: EXPERIMENTAL
Intervention: Combination treatment with Chaihu Droplet pill (CHDP) and Huoxiang Zhengqi Droplet pill (HZDP) for 13 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Symptomatic treatment only (Control)
Number of subjects: 22
Study: 11448297

Group type: EXPERIMENTAL
Intervention: Individual cognitive behavioral therapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sertraline therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (nondepressed healthy subjects)
Number of subjects: 14
Study: 9881239

Group type: EXPERIMENTAL
Intervention: Human insulin (group B, n = 46)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Animal insulin (group A, n = 48)
Number of subjects: 94
Study: 7674870

Group type: EXPERIMENTAL
Intervention: Choline bitartrate (2.43 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2282973

Group type: EXPERIMENTAL
Intervention: 2 g ampicillin plus 1 g sulbactam, given intravenously every 6 h
Number of subjects: 54

Group type: COMPARATOR
Intervention: 2 g cefoxitin, given intravenously every 6 h
Number of subjects: 54
Study: 6111570

Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Parenteral morphine
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Oxycodone compound (equivalent to 12.5 mg morphine)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 31654725

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention conducted between November 2014 and June 2015
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1129
Study: 30840084

Group type: EXPERIMENTAL
Intervention: Positive Affect (PA) intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Education (EDU)
Number of subjects: 120
Study: 28701228

Group type: EXPERIMENTAL
Intervention: Single application of 4% chlorhexidine (CHX) at birth
Number of subjects: 4760

Group type: COMPARATOR
Intervention: Dry cord care
Number of subjects: 4760
Study: 25433727

Group type: EXPERIMENTAL
Intervention: Hands-on gel phantom training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Instructional video training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study: 23650124

Group type: EXPERIMENTAL
Intervention: Topical capsaicin 8% (Qutenza)
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Topical low-dose capsaicin 0.04% (active control)
Number of subjects: 1248
Study: 21247484

Group type: EXPERIMENTAL
Intervention: AMA1‐C1/Alhydrogel
Number of subjects: 300

Group type: COMPARATOR
Intervention: Hiberix
Number of subjects: 300
Study: 19589145

Group type: EXPERIMENTAL
Intervention: Patient Advocate Crisis Plan (PACP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinician facilitated Crisis Plan (CCP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no psychiatric advance statement)
Number of subjects: 0
Study: 17717313

Group type: EXPERIMENTAL
Intervention: OCSP diagnosis of lacunar stroke within 6 hours of onset
Number of subjects: 1367

Group type: EXPERIMENTAL
Intervention: Patients classified as OCSP 'LACS' within 6 hours
Number of subjects: 1367
Study: 15464767

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (200 microg/tablet, 2 tablets)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous methylergometrine (200 microg, 1 ml)
Number of subjects: 120
Study: 11209832

Group type: EXPERIMENTAL
Intervention: Participatory ergonomics program
Number of subjects: 0
Study: 9609606

Group type: EXPERIMENTAL
Intervention: Provocation with perfume for 5 minutes (nose clip on)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Provocation with perfume for 30 minutes (nose clip on)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Provocation with perfume for 5 minutes (no nose clip)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Provocation with saline (placebo)
Number of subjects: 10
Study: 7820061

Group type: EXPERIMENTAL
Intervention: Splenectomy after complete response (CR) to alpha interferon (IFN) therapy
Number of subjects: 169

Group type: COMPARATOR
Intervention: Maintenance therapy
Number of subjects: 169

Group type: COMPARATOR
Intervention: Alpha interferon (IFN) therapy
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 169
Study: 2040042

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg qd
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 7402084

Group type: EXPERIMENTAL
Intervention: Ethinyl oestradiol 50 micrograms/day + norgestrel 250 micrograms/day
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Nordiol (combination of ethinyl oestradiol and norgestrel)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 49
Study: 31583253

Group type: EXPERIMENTAL
Intervention: Trigonella foenum‐graecum seed powder solution (25g orally twice a day for one month)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Metformin (control group)
Number of subjects: 114
Study: 28756607

Group type: EXPERIMENTAL
Intervention: Dralitem® (200 mg/m2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Temodal® (200 mg/m2)
Number of subjects: 16
Study: 26449997

Group type: EXPERIMENTAL
Intervention: KIM-1 levels measured at baseline
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: KIM-1 levels measured at 48-72 hours
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: KIM-1 levels measured at 30 days
Number of subjects: 874
Study: 24456668

Group type: EXPERIMENTAL
Intervention: Brief online intervention comprising assessment, normative feedback, and advice on reducing drinking.
Number of subjects: 55000

Group type: COMPARATOR
Intervention: Delayed access to online intervention (Control group).
Number of subjects: 55000
Study: 21402611

Group type: EXPERIMENTAL
Intervention: Immunophenotypic response (IR)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Complete response (CR)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Stringent complete response (stringent CR)
Number of subjects: 102
Study: 19672655

Group type: EXPERIMENTAL
Intervention: AVAPS ventilation
Number of subjects: 9

Group type: COMPARATOR
Intervention: PS ventilation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: AVAPS and PS ventilation
Number of subjects: 9
Study: 17318558

Group type: EXPERIMENTAL
Intervention: Acupressure therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin B6
Number of subjects: 0
Study: 15042607

Group type: EXPERIMENTAL
Intervention: Screening (serum PSA measurement and digital rectal examination)
Number of subjects: 46486

Group type: COMPARATOR
Intervention: No screening (unscreened controls)
Number of subjects: 46486
Study: 11303306

Group type: EXPERIMENTAL
Intervention: Hispanics and African Americans in the prospective cohort
Number of subjects: 161

Group type: COMPARATOR
Intervention: Whites
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Larger combined prospective and retrospective groups of SSc patients
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: HLA-DQB1*0301
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: HLA-DRB1*11
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: HLA-DRB1*01, DRB1*04, and DQB1*0501
Number of subjects: 161
Study: 9931779

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open approach and transinguinal procedure
Number of subjects: 100
Study: 8140488

Group type: EXPERIMENTAL
Intervention: Single 1 g dose of azithromycin
Number of subjects: 183

Group type: COMPARATOR
Intervention: 100 mg doxycycline twice daily for seven days
Number of subjects: 183
Study: 3073880

Group type: EXPERIMENTAL
Intervention: L-thyroxine treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30309406

Group type: EXPERIMENTAL
Intervention: 0.9% NaCl solution
Number of subjects: 280

Group type: COMPARATOR
Intervention: Ringer solution
Number of subjects: 280

Group type: COMPARATOR
Intervention: ASPMCG solution
Number of subjects: 280
Study: 27581533

Group type: EXPERIMENTAL
Intervention: 80 mg telmisartan/5 mg amlodipine/12.5 mg hydrochlorothiazide (T80/A5/H12.5)
Number of subjects: 132

Group type: COMPARATOR
Intervention: 80 mg telmisartan/12.5 mg hydrochlorothiazide (T80/H12.5)
Number of subjects: 132
Study: 26130347

Group type: EXPERIMENTAL
Intervention: TGF-ß1-expressing chondrocytes
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 23599318

Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 810

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Surgery (fundoplication)
Number of subjects: 810
Study: 21263351

Group type: EXPERIMENTAL
Intervention: Water Works Douching Device
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (over-the-counter plastic douching device)
Number of subjects: 140
Study: 18958161

Group type: EXPERIMENTAL
Intervention: Self-face recognition in children with ASD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-face recognition in typically developing (TD) children
Number of subjects: 0
Study: 16698053

Group type: EXPERIMENTAL
Intervention: Antivenom A
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Antivenom B
Number of subjects: 67

Group type: COMPARATOR
Intervention: Both antivenoms
Number of subjects: 67
Study: 12743006

Group type: EXPERIMENTAL
Intervention: HCM patients with VF
Number of subjects: 266

Group type: COMPARATOR
Intervention: HCM patients without VF
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: DCM patients with VF
Number of subjects: 266

Group type: COMPARATOR
Intervention: DCM patients without VF
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: LQTS patients with VF
Number of subjects: 266

Group type: COMPARATOR
Intervention: LQTS patients without VF
Number of subjects: 266
Study: 12607205

Group type: EXPERIMENTAL
Intervention: Fluoxetine (40 mg/day) plus misoprostol (500 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacine (100 mg/day) plus misoprostol (500 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus misoprostol (500 mg/day)
Number of subjects: 0
Study: 8835807

Group type: EXPERIMENTAL
Intervention: Bathing after admission assessment (M = 61.15 minutes of age)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard bathing at 4 hours of age (M = 252.12 minutes of age)
Number of subjects: 100
Study: 1598427

Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg/day for 30 days)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg/day for 30 days)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (healthy volunteers without treatment)
Number of subjects: 43
Study: 6144128

Group type: EXPERIMENTAL
Intervention: 200 mg zimelidine each morning for 5 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg temazepam 2 h after zimelidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30102413

Group type: EXPERIMENTAL
Intervention: Selumetinib (75 mg twice daily) plus docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selumetinib (75 mg twice daily)
Number of subjects: 0
Study: 29117073

Group type: EXPERIMENTAL
Intervention: Yerba Mate (YM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 11
Study: 26932437

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (CRT) using a moderate radiation dose weekly combined with carboplatin and paclitaxel followed by surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (CRT)
Number of subjects: 0
Study: 24841093

Group type: EXPERIMENTAL
Intervention: Incremental theory intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Entity theory (control)
Number of subjects: 0
Study: 23223738

Group type: EXPERIMENTAL
Intervention: Auriculotherapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control
Number of subjects: 71
Study: 20385970

Group type: EXPERIMENTAL
Intervention: Home BP
Number of subjects: 2081

Group type: COMPARATOR
Intervention: Office BP
Number of subjects: 2081

Group type: EXPERIMENTAL
Intervention: Systolic home BP
Number of subjects: 2081
Study: 18032226

Group type: EXPERIMENTAL
Intervention: Ritalin (methylphenidate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amphetamines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cocaine
Number of subjects: 0
Study: 15749500

Group type: EXPERIMENTAL
Intervention: Gynetics catheter
Number of subjects: 251

Group type: COMPARATOR
Intervention: Makler cannula
Number of subjects: 251
Study: 11865270

Group type: EXPERIMENTAL
Intervention: Cycled light (CL) from birth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cycled light (CL) at 32 weeks' PCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cycled light (CL) at 36 weeks' PCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Near darkness (ND) until 36 weeks' PCA
Number of subjects: 0
Study: 10468165

Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 394

Group type: COMPARATOR
Intervention: Diclofenac retard
Number of subjects: 394
Study: 8574252

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 30 micrograms and gestodene 75 micrograms (oral contraceptives)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (diabetic women not taking OCs)
Number of subjects: 11
Study: 2150580

Group type: EXPERIMENTAL
Intervention: Nafarelin (400 micrograms/day intranasally)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Danazol (600 mg/day orally)
Number of subjects: 18
Study: 758493

Group type: EXPERIMENTAL
Intervention: Combination of dihydroergotamine and heparin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Heparin calcium
Number of subjects: 300

Group type: COMPARATOR
Intervention: Dihydroergotamine mesylate
Number of subjects: 300
Study: 31036625

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 3 months (Q3M)
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months (Q6M)
Number of subjects: 654

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654
Study: 27402913

Group type: EXPERIMENTAL
Intervention: 6-thioguanine nucleotide (6-TGN) concentrations at T1
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: 6-methylmercaptopurine ribonucleotide (6-MMPR) concentrations at T1
Number of subjects: 194

Group type: COMPARATOR
Intervention: Mercaptopurine treatment
Number of subjects: 194

Group type: COMPARATOR
Intervention: Concurrent anti-TNF therapy
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Elevations of both T1 6-TGN and 6-MMPR
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Exceeding only the T1 6-MMPR or 6-TGN threshold concentration
Number of subjects: 194
Study: 25129372

Group type: EXPERIMENTAL
Intervention: Caudal extension graft (CEG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Columellar strut with plumping graft (CSPG)
Number of subjects: 0
Study: 23410235

Group type: EXPERIMENTAL
Intervention: Diagnosis threat (DT) group (n=15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Reduced threat (DT-reduced) group (n=15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Neutral group (n=15)
Number of subjects: 45
Study: 21836105

Group type: EXPERIMENTAL
Intervention: Standard care plus yoga for 3 months
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 123
Study: 19492974

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0